Latest Bosentan Stories
Can these drugs help with a wider array of diseases? Expert to address conference of experts Being sponsored by the American Physiological Society (APS).
SOUTH SAN FRANCISCO, Calif., Sept.
Data Findings Published in June Issue of Circulation SILVER SPRING, Md.
SILVER SPRING, Md., BOSTON and SOUTH SAN FRANCISCO, Calif., May 18 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA), Tufts Medical Center, and Actelion Pharmaceuticals US, Inc., today announced Dr.
LIBERTY CORNER, N.J., Feb. 23 /PRNewswire/ -- GeneraMedix, Inc.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1).
LAVAL, QUEBEC--(Marketwire - Sept.
Actelion has announced that Tracleer, a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension.
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy that improves exercise capacity by a greater percentage than Actelion's Tracleer at 16 weeks, would earn a 48 percent patient share in the treatment of pulmonary arterial hypertension, according to surveyed pulmonologists.
SILVER SPRING, Md. and SOUTH SAN FRANCISCO, Calif., June 23 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA) and Actelion Pharmaceuticals US, Inc. today announced Robyn Barst as the recipient of the second annual PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care.
- A woman chauffeur.
- A woman who operates an automobile.